← Leaderboards
Hyesook Kim
Detroit R & D, Inc.
$1,696,653
Attributed
$1,696,653
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $990K · FY2011–19$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$1,696,653 · 4
By mechanism
N44$1,000,313 · 1
N43$446,617 · 2
N01$249,723 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsSmall Business Innovation Research GrantSignal TransductionProductionApoptosisSiteNormal CellAntigensPeptidesPlayInhibitor/AntagonistResponseCancer CellAntibody FormationPeptide AntibodiesDetectionModificationC-Myc GenesAntibodiesPeptide O-Linked N-Acetylglucosamine-Beta-N-AcetylglucosaminidaseCell Cycle RegulationPhosphorylationProteinsLabel
Grant awards (5)
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER$10,338
N44 · FY2019 · CA · contact PI
SBIR Topic 97 - Multiplex Label-Free Nanowell Technology for Early Cardiotoxicity Biomarkers - Phase I$249,723
N01 · FY2016 · HL · contact PI
IGF::OT::IGF R&D- MEDICAL: BIOMEDICAL (BASIC RESEARCH)$299,097
N43 · FY2015 · CA · contact PI
SBIR PHASE II: SITE-SPECIFIC ANTIBODIES FOR GLCNACYLATED PROTEINS IN CANCER$989,975
N44 · FY2013 · CA · contact PI
SBIR TOPIC 294 PHASE I - DEVELOPMENT OF GLYCOSYLATION-SPECIFIC RESEARCH REAGENTS$147,520
N43 · FY2011 · CA · contact PI